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Effective and validated animal models are valuable to investigate the pathogenesis and potential therapeutics for
human diseases. There is much concern for diabetic retinopathy (DR) in that it affects substantial number of
working population all around the world, resulting in visual deterioration and social deprivation. In this review, we
discuss animal models of DR based on different species of animals from zebrafish to monkeys and prerequisites for
animal models. Despite criticisms on imprudent use of laboratory animals, we hope that animal models of DR will
be appropriately utilized to deepen our understanding on the pathogenesis of DR and to support our struggle to
find novel therapeutics against catastrophic visual loss from DR.
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Introduction
Systemic control of blood glucose can slow down the
progression of diabetic retinopathy (DR), but fails to stop
or reverse clinical signs of DR [1,2]. Furthermore, al-
though general mechanisms of DR are yet to be eluci-
dated, researchers have discovered various molecular
pathways regarding DR. In this regard, local treatment
options as well as systemic therapeutics of pathogenesis-
based approaches are desperately required to prevent
catastrophic visual loss from vision-threatening compli-
cations of DR such as macular edema (ME), vitreous
hemorrhage (VH), and tractional retinal detachment
(TRD). Despite criticisms on imprudent uses of labora-
tory animals, validated animal models are valuable tools
to deepen our understanding on the pathogenesis of
human diseases and estimate the therapeutic potential of
candidate drugs.
As for DR, there are several animal models based on
different species of animals from zebrafish to monkeys.* Correspondence: steph25@snu.ac.kr
1Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical
Research Institute, Seoul National University, Seoul 110-744, Republic of
Korea
3Department of Ophthalmology, College of Medicine, Seoul National
University, Seoul 110-744, Republic of Korea
Full list of author information is available at the end of the article
© 2013 Jo et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orSome are based on hyperglycemia that occurs spontan-
eously or is induced by chemical agents or surgical oper-
ation; others mimic clinical consequences of DR and
share the molecular pathogenesis of DR. Unfortunately,
currently available animal models have limitations in
that they only show certain aspects of DR and do not re-
flect human pathology exactly in the view of retinal
structures and mediating factors. Therefore, researchers
who utilize animal models of DR should choose animal
models that suit for purposes of their research.
In this review, we provide a summary of pathologic
features of DR and therapeutic goals in the treatment of
DR for further discussion on the selection of appropriate
animal models of DR. Then, animal models of DR based
on various animals including zebrafish, mice, rats, dogs,
and monkeys are listed with details on brief protocols
for selected animal models. We hope that this review
will help researchers to select appropriate animal models
in the investigation of pathogenesis and therapeutic
approaches regarding DR.Pathologic changes in patients with DR
Largely, DR is divided into 2 subgroups, nonproliferative
DR (NPDR) and proliferative DR (PDR), according to
the presence of retinal neovascularization. That is, PDR
indicates the condition with retinal neovascularizationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the Early Treatment of Diabetes Retinopathy Study
(ETDRS) defined mild, moderate, severe NPDR, and
PDR, based on presence of structural abnormalities in
the retina, the degree of retinal neovascularization, and
accompanying vitreous and/or preretinal hemorrhage
[3]. Furthermore, the more practical scale was devised
with the sponsorship provided by American Academy of
Ophthalmology, which has been utilized widely in every-
day clinical settings [4]. In this scale, mild NPDR indi-
cates the condition that there are only microaneurysms
in the retina. Severe NPDR is characterized by any of
the following retinal abnormalities: 1) more than 20
intraretinal hemorrhages in each of 4 quadrants of the
retina, 2) definite venous beading in 2 or more quad-
rants of the retina, and 3) prominent intraretinal micro-
vascular abnormalities (IRMA) in 1 or more quadrant of
the retina. Moderate NPDR is defined as the condition
between mild and severe NPDR. Pathologic changes in
patients with DR are demonstrated in Figure 1.
Alterations in retinal structures
In clinical settings, the severity of NPDR is determined
by the presence of alterations in retinal structures such
as microaneurysms, retinal hemorrhages, venous bead-
ing, and IRMA. Microaneurysms are known to occur
with thickening of the capillary endothelial basementFigure 1 Pathologic changes in patients with DR. (A) Microaneurysm is
by tiny hyperfluorescent spots in the fluorescein angiography. (B) Disruptio
DR patients. Optical coherence tomography demonstrates cystoid ME. (C) I
Fibrovascular proliferation from retinal neovascularization forms diffuse tracmembrane (BM) and pericyte loss induced by hypergly-
cemia [5]. This is because many researchers paid atten-
tion to corresponding structural abnormalities in various
animal models of DR [6]. Venous beading, the manifest-
ation of focal areas of venous dilatation, and IRMA,
demonstrated with tortuous intraretinal vessels, indicates
the progression of DR clinically and at the same time
reflects ischemia and alterations in retinal structures in
the view of pathologic conditions. Interestingly, these
structural abnormalities progress with time [7]; there-
fore, they are appropriate barometers for DR as well as
clinical signs which require great attention for clinicians
who treat patients with DR.
Disruption of neurovascular units: breakdown of blood-
retinal barrier (BRB) to ME
The macula is the central concave area of the retina of
which diameter is 5,000 μm. The concavity of the
macula helps photoreceptor cells in the central retina to
receive the light more effectively than those in surround-
ing areas. In contrast, patients with ME lose this concav-
ity in the macular area, resulting in blurred vision. In
DR, even before the severity reaches the level of PDR,
ME can occur to jeopardize the clarity of the vision.
Especially, ME located in the most central area of the
retina is called clinically significant ME (CSME) [8].
CSME is defined by the ETDRS research group asone of the characteristic findings in patients with NPDR, demonstrated
n in neurovascular units and breakdown of inner BRB leads to ME in
n PDR patients, VH can occur from fragile new vessels. (D)
tional membrane, resulting in TRD.
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500 μm of the center of the macula, 2) hard exudates at
or within 500 μm of the center of the macula with thick-
ening of adjacent retina, or 3) a zone of retinal thicken-
ing larger than 1 disc area if located within 1 disc
diameter (1,500 μm) of the center of the macula [9].
ME is the phenomenon induced by the disruption of
inner BRB, the endothelial barrier constructed by an
extensive network of neurovascular units [10]. Neuro-
vascular units indicate robust interactions among neu-
rons, glial cells including astrocytes, periendothelial cells
such as pericytes, and endothelial cells to allow the func-
tional integrity of neurons and the formation of blood-
neural barriers, BRB and blood–brain barrier [10,11].
Recently, much effort is focused in the development
of therapeutic agents which improve the integrity of
neurovascular units in central nervous system such as
Alzheimer’s disease, stroke, and Parkinson’s disease [11].
Interestingly, most candidate drugs for DR, currently on
clinical trials, also mainly target ME [12]. Because
various mechanisms regarding DR are involved in the
disruption of inner BRB, therapeutics targeting these
pathologic pathways might help to reduce visual deteri-
oration from ME. Mechanisms regarding the pathogen-
esis of DR include hypoxia, inflammation, oxidative
stress, and growth factors such as vascular endothelial
growth factor (VEGF) [12,13]. These factors influence
the vascular permeability and further induce leakage of
serum constituents into retinal tissues, resulting in ME.
Pathologic angiogenesis to VH and TRD
In PDR, ME also occurs from progressive and chronic de-
terioration in the integrity of the endothelial barrier system.
Furthermore, retinal neovascularization from the retinal
vasculature in inner retinal layers extends into the vitreous
cavity [14]. Like pathologic angiogenesis in the tumor vas-
culature, retinal neovascularization in DR tends to be fra-
gile and leaky, which can induce further complications
from it [15]. In this regard, ruptured neovascularization
results in VH, preventing the light from objects to reach
the neurosensory retina. In addition, extracellular matrix
proteins and fibrous materials can accumulate around new
vessels in the retina; this fibrogenic reaction is accelerated
by growth factors such as transforming growth factor-β
[16]. Unfortunately, fibrovascular tissues formed in the
progression of PDR evolve into tractional membrane which
can pull the neurosensory retina from underlying tissues,
resulting in TRD. Especially, TRD involving the central
retina induce visual disturbances in patients with PDR.
Concerns in care for patients with DR: pathogenesis-
based treatment
Advancements in our knowledge of the pathogenesis of
DR should lead to the development of pathogenesis-based treatment for the prevention of vision loss in the
patients with DR. Unfortunately, current treatment op-
tions for DR do not fulfill these tasks effectively in that
they only prevent further complications and fail to re-
verse already occurred structural abnormalities or ad-
dress only a part of the pathogenesis of DR [12,13].
Possibly, ongoing research with animal models of DR
might enable pathogenesis-based treatment options to
be utilized in everyday clinical settings.
Drawbacks of current treatment options
Currently, patients with DR receive combinations of
treatment options including systemic control of blood
glucose and pressure, surgery, laser photocoagulation,
and intravitreal injection of steroid or anti-VEGF agents
[11-13]. Although good glycemic control is one of pre-
requisites in the care of DR patients, clinical signs of DR
can progress and sometimes result in vision-threatening
complications even after intensive hypoglycemic treat-
ment [1,2]. Therefore, local treatment options are im-
portant to prevent progressive visual deterioration from
DR. Panretinal photocoagulation (PRP) is performed in
patients with high-risk characteristics of PDR and high
probability to advance to high-risk PDR [17,18]. High-
risk characteristics include following features: 1) new
vessels that are larger than one-third disc area and
within 1 disc diameter from the optic nerve head (new
vessels at the optic disc, NVD) and 2) vitreous or
preretinal hemorrhage with NVD less than criteria 1) or
new vessels elsewhere that are larger than one-quarter of
disc area [3]. Definitely, PRP prevents the occurrence of
further complications from DR; however, PRP is a rela-
tively destructive procedure in that it sacrifices the per-
ipheral retina with the purpose of saving the central
vision. Likewise, focal photocoagulation, performed for
the patients with ME, also blocks further leakage to
decrease the frequency of persistent ME, but induces
minor visual field losses [9,19]. Furthermore, despite of
the preventive potential for the progression of complica-
tions, laser photocoagulation has limitations in that it
only addresses the consequences of pathologic events.
Recently, peeling of inner limiting membrane is perfor-
med for the patients with ME to lower mechanical
forces regarding the formation of ME [20]. However,
without the control of vascular permeability, the effect
of surgery on the visual outcome is not substantial. Still,
surgery is reserved for the patients with refractory VH
or severe TRD involving the fovea [21].
Intravitreal injection of therapeutic agents such as
steroids and anti-VEGF agents is relatively invasive
compared to laser photocoagulation or systemic hypo-
glycemic therapy. Intravitreal administration of triamcin-
olone acetate (IVTA) fails to show a long-term benefit
compared to focal photocoagulation in patients with ME
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treatment are likely to undergo cataract surgery. In
contrast, in patients with pseudophakia, IVTA is still
one of therapeutic options for ME because this addresses
broadly on inflammatory natures of ME by suppression
of inflammatory mediators [12]. Intravitreal injection of
anti-VEGF agents such as ranibizumab (Genetech, Inc.,
South San Francisco, CA, USA), pagaptanib (Eyetech
Pharmaceuticals, Inc., Lexington, MA, USA), aflibercept
(Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA),
and bevacizumab (Genetech, Inc.) effectively suppresses
complications from choroidal neovascularization in wet
age-related macular degeneration (AMD) and shows
beneficial effects in visual outcomes [13]. Also in DR,
these drugs demonstrate positive efficacy on suppression
of ME and restoration of vision [22-25]. However,
chronic and relapsing nature of ME in DR requires
multiple intravitreal injections (over 5 times) per year;
therefore, more stable and effective therapeutic agents
are still required for the treatment of DR. Furthermore,
VEGF inhibition basically has a risk of complications in
that VEGF not only induces pathologic angiogenesis and
hyperpermeability but also acts as trophic factors for
neuronal cells and normal endothelial cells [26-28]. In
this regard, pathogenesis-based therapeutic options are
to be developed to optimize our armamentarium against
DR and minimize potential toxicities; appropriate use of
animal models of DR will accelerate these development
processes effectively. Currently, bevacizumab is utilized
as the off-label drug; the approved indication of pegap-
tanib and aflibercept does not include DR, but AMD;
and the approved indications of ranibizumab include
both AMD and DR.
Therapeutic goals in treatment of DR patients
To overcome drawbacks of current treatment options,
researchers might bear in mind the therapeutic goals in
the treatment of DR. First of all, the restoration of func-
tional integrity of the retina is important. This objective
includes restoration of neurovascular units and the in-
tegrity of BRB. As previously mentioned, neurovascular
units cover various types of cells and interactions among
them via cell to cell contacts and secretory mediators
[10,11]. As DR progresses, normal cellular communica-
tion is altered with increased level of growth factors such
as VEGF and inflammatory cytokines [11]. Further dis-
ease progression leads to disruption of tight junction
proteins in endothelial cells, resulting in breakdown of
inner BRB [29]. In this regard, detailed investigation of
specific roles of different kinds of cells and mediators in
animal models will definitely help the development of
more pathogenesis-based therapeutic options for ME.
Pathologic angiogenesis, that is, retinal neovasculariza-
tion, is another therapeutic target of DR. Interestingly,retinal new vessels progress with close contact with com-
ponents of vitreous cavity [14]. Therefore, to treat retinal
neovascularization and prevent complications from it such
as VH and TRD, both pathologic angiogenesis and inter-
action between endothelial cells and vitreous proteins can
be targeted. In this regard, anti-VEGF agents are utilized to
minimize the events of post-vitrectomy VH in PDR pa-
tients [30]. Furthermore, the therapeutic approach address-
ing interaction between endothelial cells and fibronectin in
vitreous cavity was investigated to suggest the potential of
a different treatment approach [14]. We expect that animal
models of retinal neovascularization from inner retinal
layers will promote this kind of advancement in the devel-
opment of novel therapeutics based on different molecules
and approaches.
Prerequisites for effective and validated animal models of
DR
In prior sections, we review pathologic changes in pa-
tients with DR and therapeutic approaches to treat these
patients. Currently, validated animal models are at the
center of the development process of novel therapeutic
agents and modalities. Before clinical trials, candidate
drugs undergo scrutinization through in vitro assays and
in vivo animal models. Although there is great need for
the development of the intermediate stage of disease-
mimicking chips to minimize uncontrolled use of labora-
tory animals, assays between in vitro assays and in vivo
animal models are still lacking. Therefore, we cannot
help resorting to validated animal models in the research
of pathogenesis and therapeutic applications of DR.
To minimize the imprudent use of laboratory animals
and at the same time obtain reproducible results,
validated animal models of DR should show following
characteristics as prerequisites: 1) Reflecting human
pathology. As for structural abnormalities such as
microaneurysm and accompanying functional abnormal-
ities such as increased permeability, researchers expect
those features to be reproducibly manifested in validated
animal models. 2) Easy maintenance of animals. Too
large or too weak animals require special care for the
maintenance. These animals are not suitable for re-
peated experiments with stable and reproducible results.
3) Easy induction of diabetic or pathologic conditions.
Animal models based on complicated surgery or long-
term feeding can promote research on those specific
treatment options, but hinder widespread use of animal
models. 4) Validated methods of data interpretation.
Especially in the models for the evaluation of therapeutic
effects, findings should be analyzed statistically to dem-
onstrate therapeutic potential of candidate drugs. In this
process, proper randomization of laboratory animals and
handling of data are mandatory to optimize the predict-
ive value of studies [31].
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As research on diabetes is actively performed, there are
several validated animal models for diabetes and some of
them are utilized for the investigation of DR. These
animal models basically demonstrate induced hypergly-
cemia as the main characteristic of animal models. In
other words, the elevation of serum glucose that is spon-
taneously, chemically, or surgically induced leads to
pathologic events similar to those in patients with dia-
betes and DR. As previously mentioned, animal models
of this category show the pathologic features regarding
structural abnormalities or the dissociation of neurovas-
cular units of the retina: 1) pericyte loss, 2) thickening of
BM, 3) acellular capillaries or capillary dropout, and 4)
increased vascular permeability. Unfortunately, retinal
neovascularization in DR is not definite in animal
models of DR with induced hyperglycemia [6]. In this
regard, researchers have utilized animal models of retinal
neovascularization for studying the therapeutic potential
of candidate drugs on the status of PDR [14,32,33].
Furthermore, intravitreal and subretinal injection of
angiogenic factors such as VEGF also leads to retinal
neovascularization or increased vascular permeability
[34,35]. In following sections, we review various animal
models of DR based on different species of animals from
zebrafish to monkeys. Characteristics of each animal
model are summarized in Table 1.
Zebrafish
Zebrafish are valuable tools for high throughput screening
of candidate drugs and investigation of cell to cell interac-
tions in normal or pathologic conditions. Particularly, it is
relatively easy to handle multiple zebrafish at the labora-
tory facility because they are so tiny that occupy relatively
small space. Furthermore, the introduction of fli1:EGFP
zebrafish which show the fluorescent expression of vascu-
lar structures makes zebrafish-based models more attract-
ive for the investigation of vascular abnormalities regarding
pathologic conditions [36].
High glucose-induced models
Zebrafish are known to demonstrate a similar metabolic
regulation of glucose as human and mice [37]. Immers-
ing the fish in 2% glucose solution every other day for
28 days induces hyperglycemia [38]. Generally, hypergly-
cemia possibly leads to apoptosis of neuronal and peri-
vascular cells and atrophy of retinal layers. Interestingly,
alternate exposure to glucose/water solutions results in
thinning of the inner plexiform and inner nuclear layers
(IPL and INL, respectively) and the ratio of IPL to INL
is decreased by nearly 45% [38]. Furthermore, the same
treatment demonstrates deleterious effects on cone
photoreceptor cells, evidenced by definite degeneration
of the photoreceptor cell layer (PL) and alterations incone-mediated electroretinogram [39]. In this regard,
this model helps researchers to dig out the cellular re-
sponse to hyperglycemia and further pathologic changes
in the diabetic retina. In addition, electron microscopy
studies show that the width of interendothelial junctions
and the thickness of BM in retinal capillaries are in-
creased, suggesting the disruption of neurovascular units
and inner BRB in this model [39]. As injection of tracers
of different molecular sizes can be utilized for the dem-
onstration of relative vascular permeability, we expect
that this zebrafish model will be an animal model for
high throughput screening of candidate drugs to control
vascular permeability [36].
Streptozocin promotes cytotoxicity of β cells of pan-
creas to induce hyperglycemia in various animals includ-
ing mice and rats [40-45]. Likewise, intraperitoneal
injection of streptozocin in zebrafish leads to hypergly-
cemia and further characteristic findings corresponding
to DR such as thinning of IPL and PL [46]. Such univer-
sal responses to hyperglycemia in zebrafish as mammals
make DR models in zebrafish to be attractive animal
models to investigate the pathogenesis of DR.
Hypoxia-induced pathologic angiogenesis and vascular
changes
In mice, rats, and dogs, oxygen-induced retinopathy
(OIR) models are widely utilized for the investigation
of retinal neovascularization [47-50]. Although these
models do not show hyperglycemia, it is worth mention-
ing these models in this review on animal models of DR
in that they are validated animal models of retinal
neovascularization, the prominent clinical finding of
PDR. Exposure to hyperoxia leads to the induction of
cellular and histologic responses to hypoxia on returning
to the normal condition. In this regard, OIR models can
be utilized in studies on pathologic angiogenesis regard-
ing hypoxia. Currently, there is no animal model using
this concept in zebrafish. However, placing zebrafish
in hypoxic water for 3 to 10 days results in retinal
neovascularization, demonstrated by increased vascular
sprouts in flat-mounted zebrafish retina [51,52]. As pre-
viously mentioned, vascular structures are easily visual-
ized in fli1:EGFP zebrafish. Furthermore, with this
model, researchers can quantitatively analyze the efficacy
of candidate drugs which are diluted in the solution and
systemically applied to zebrafish [51].
Mice and rats
Most of animal models of DR are based on rodents,
mice and rats. We speculate that we cannot cover all
published animal models and may skip some in this
review because we intentionally include widely utilized
and validated animal models. Interestingly, rodent
models of DR are largely divided into 3 subgroups: 1)
Table 1 A list of animal models of DR that are based on various species from zebrafish to monkeys
Animal model Method of induction Type of diabetes Characteristic findings References
Zebrafish
High glucose treatment Alternate immersing in
glucose/water solution
Type 1 - Thinning of IPL and INL [38,39]
- Degeneration of PL
- BM thickening in retinal capillaries
STZ Intraperitoneal injection of STZ Type 1 - Thinning of IPL and PL [46]




STZ Intraperitoneal injection of STZ Type 1 - BM thickening in
retinal capillaries
[29,35,41-45,53]
- Apoptosis of neuronal
cells in GCL
- Loss of pericytes in
retinal capillaries
- Loss of amacrine cells in INL
- Increased vascular permeability
db/db mice Spontaneous hyperglycemia Type 2 - BM thickening in
retinal capillaries
[54-59]
- Loss of pericytes
- Apoptosis of neuroretinal cells
- Increased vascular permeability





Akita mice Spontaneous hyperglycemia Type 1 - Apoptosis of neuronal
cells in GCL
[45,63,64]
- Loss of amacrine cells in INL
- Acellular capillaries
- Loss of pericytes
- Thinning of IPL and INL
- Increased vascular permeability
- Microaneurysm formation
- New vessels in OPL
Zucker diabetic
fatty rats
Spontaneous hyperglycemia Type 2 - BM thickening in retinal capillaries [65-67]








- Thinning of INL and PL
Goto-Kakizaki rats Spontaneous hyperglycemia Type 2 - Apoptosis of ECs [72-74]
- Decreased retinal circulation
Kimba mice Transgenic overexpression of VEGF165 gene N/A - Increased vascular permeability [77,78]
- Retinal neovascularization
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Table 1 A list of animal models of DR that are based on various species from zebrafish to monkeys (Continued)
OIR Exposure to hyperoxia during
early postnatal periods
N/A - Increased vascular permeability [47-49,79]
- Retinal neovascularization
Akimba mice Crossing Akita mice with Kimba mice Type 1 - Thinning of PL [80]
- Loss of ganglion cells in GCL
- Capillary nonperfusion
- Retinal neovascularization
Diabetic Torii rats Spontaneous hyperglycemia Type 2 - Large retinal folds mimicking TRD [81-83]
- Massive hemorrhage in A/C
- Acellular capillaries
- Loss of pericytes
Dogs




OIR Exposure to hyperoxia during
early postnatal periods
N/A - Retinal neovascularization [50,87]
- Peripheral retinal ischemia
- Vitreous hemorrhage
- Tractional retinal folds
Monkeys
Spontaneously diabetic Spontaneous hyperglycemia Type 2 - IRMA [88,89]
- Microaneurysm formation
- Retinal hemorrhage
A/C Anterior chamber, BM Basement membrane, EC Endothelial cell, GCL Ganglion cell layer, INL Inner nuclear layer, IPL Inner plexiform layer, IRMA Intraretinal
microvascular abnormality, N/A Not applicable, NVD New vessels at the optic disc, OPL Outer plexiform layer, PL Photoreceptor cell layer, STZ Streptozocin, TRD
Tractional retinal detachment.
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diabetic models, and 3) models with definite retinal
neovascularization. The first 2 subgroups basically reflect
structural abnormalities in DR without proliferative
characteristics. In contrast, the latter is a valuable tool
to investigate the molecular components of retinal
neovascularization and therapeutic potential of candi-
date therapeutics in the treatment of PDR.
Models with induced hyperglycemia
Streptozocin-induced death of pancreatic β cells leads to
hyperglycemia in mice and rats. In mice, 1 or 2 days
after the intraperitoneal injection of streptozocin, the
level of serum glucose reaches above 350 mg/dl. Inter-
estingly, the thickness of BM of retinal capillaries is
increased in streptozocin-induced diabetic mice and rats
[41,44]. Cell death of components of neurovascular units
is also observed in both models. Neuronal cells in the
ganglion cell layer (GCL) undergo apoptotic cell death
in the streptozocin induced mice model [42]. In addition
to neuronal cell death, chronic elevation of serum glu-
cose induces degeneration and selective loss of pericytesof retinal capillaries in streptozocin-induced diabetic rats
[43]. Furthermore, the number of amacrine cells is de-
creased in diabetic rats induced by streptozocin [45].
This loss of neuronal cells might be the reason of the
phenomenon that certain layers of the diabetic retina are
thinner than those in normal control.
As previously mentioned, increased vascular perme-
ability and further ME are targets of therapeutic
application in DR. Interestingly, streptozocin-induced
hyperglycemia promotes vascular permeability in a week
(Figure 2). After the induction of vascular permeability,
suppressive effect of candidate drugs on vascular perme-
ability is analyzed with the intravitreal administration of
candidate drugs for 24 hours [29,35,53]. The schematic
protocol of the streptozocin-induced hyperpermeability
model is demonstrated in Figure 3.
Spontaneously diabetic models
Certain strains of mice and rats demonstrate hypergly-
cemia during the lifetime. Full coverage of detailed
characteristics of each model is beyond the purpose and
scope of this review; therefore, we focus the introduction
Figure 2 Animal models of DR demonstrating increased vascular permeability (A) and retinal neovascularization (B). (A) Intraperitoneal
injection of streptozocin to mice leads to hyperglycemia in 2 ~ 3 days and increased vascular permeability ensues in a week. Flat-mounted retina
after the intravenous injection of FITC-dextran evidences diffuse leakage of retinal vessels. (B) Exposure to hyperoxia from P7 to P12 results in
retinal neovascularization, which starts at P14 and peaks at P17. Flat-mounted retina after the intravenous injection of FITC-dextran demonstrates
central ischemic retina with small vascular tufts at the junction between vascularized and avascular retina.
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animal models according to the purpose of studies.
db/db mice
In this model, above-mentioned structural abnormalities
such as loss of pericytes and BM thickening are observed
[54-56]. Hyperglycemia starts at 8 weeks after the birth
and mice over 18 weeks are usually utilized for the study
investigating DR, because microvascular complications are
demonstrated at this moment [57]. Interestingly, VEGF is
increased in the vitreous fluid of this mouse model at 18 to
20 weeks [58]. Elevation of VEGF and other pathologic
mechanisms such as oxidative stress might be inducing
factors of vascular permeability in this model [55,59].
Non-obese diabetic (NOD) mice
In NOD mice, the cumulative incidence of diabetic
phenomena such as polyuria, polydipsia, hyperglycemia,
glycosuria, and hypercholesterolemia is 80% in femalesFigure 3 Schematic protocols of the streptozocin-induced diabetic m
the intraperitoneal injection of streptozocin to mice, the level of serum glu
can be identified with the leakage of tracer molecules such as FITC-dextran
intravitreally and the therapeutic effects of them can be analyzed 24 hours
hyperoxia from P7 to P12 and then returned to room air. Intravitreal injecti
effects of them can be analyzed at P17.up to 30 weeks of age [60]. As other animal models of
DR, this model demonstrates apoptosis of ganglion cells
in GCL [61]. Hyperglycemia definitely affects the viabi-
lity of neuronal and perivascular cells consisting of
neurovascular units. Furthermore, focal vascular prolif-
eration appears to protrude from the retinal surface into
the vitreous cavity and vascular perfusion is decreased in
retinas from NOD mice [62]. This characteristic might
be due to increased expression of angiogenic factors
such as VEGF and endothelin-1 [61,62].
Akita (Ins2Akita) mice
This model is characterized by progressive loss of
pancreatic β cells and resultant hyperglycemia. Hyper-
glycemia starts to appear as early as 4 weeks, and micro-
vascular abnormalities and ongoing retinal new vessels
can be observed with maintenance of animals for longer
duration [63,64]. Early diabetic changes in this model
include acellular capillaries and loss of neuronal cells inice model (A) and the OIR mice model (B). (A) One or 2 days after
cose reaches above 350 mg/dl. One week later, vascular permeability
. At day 7 from streptozocin injection, candidate drugs are injected
after the injection (day 8). (B) Newborn mice are exposed to
on of candidate drugs are performed at P14 and the therapeutic
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more, increased vascular permeability is demonstrated
by the increase in vascular leakage. Interestingly, after
9 months of observation, a characteristic finding of new
vessel formation is observed in the outer plexiform layer
[64]. Although retinal neovascularization usually exists
in inner retinal layers in DR patients, the formation of
retinal new vessels in this model is itself an interesting
finding arousing researchers’ interests.
Zucker diabetic fatty rats
Genetic propensity for diabetes is only expressed in
obese males in this model [65]. Usually, rats at approxi-
mately 20 weeks of age are utilized for the experiments,
and control lean Zucker rats are examined for normal
controls [65,66]. Alike with above-mentioned animal
models, the thickness of BM of retinal capillaries is in-
creased in this model [65,66]. Furthermore, loss of endo-
thelial cells and pericytes around retinal capillaries is
observed and these characteristics can be modified with
the intravitreal injection of candidate drugs [67].
Otsuka long-Evans Tokushima fatty rats
From 5 months of age, this model demonstrates hyper-
glycemia and further microvascular complications of
diabetes [68]. Due to loss of neuronal cells by hypergly-
cemia, INL and PL are thinned in this model. BM
thickening in retinal capillaries is another characteristic
feature of this model corresponding to pathologic
changes in DR [68,69]. However, there is concern that
this model is not suitable for the investigation of
angiopathy in DR because the number of acellular capil-
laries and pericyte ghosts is not significantly increased
[70]. Researchers who have much interest in these
phenomenon should pay attention to this report, but
considering the report that mRNA level of VEGF is
increased in the retina of this model at 60 weeks of age,
this model might be utilized for the investigation of roles
of growth factors in the development of DR [71].
Goto-Kakizaki rats
This model is one of animal models mimicking type 2
diabetes. In DR, due to high osmolarity of blood, retinal
circulation is expected to be decreased. Interestingly,
retinal circulation time is prolonged in this model
compared to that in normal controls [72]. Furthermore,
VEGF expression of whole eyes is significantly increased,
suggesting a role of VEGF in the development of patho-
logic changes in this model [73]. In addition, increased
level of apoptosis of retinal microvascular cells suggests
the cytotoxic effect of hyperglycemia on endothelial cells
[74]. However, researchers should differentiate the con-
sequences of hyperglycemia from inheritable pathologic
changes not related to diabetes. Electroretinographicanalysis of this model shows that hyperglycemia and
further hypoxia do not affect functional abnormalities of
photoreceptor cells, which are evident from 4 weeks of
age [75]. Likewise, although WBN/Kob rats demonstrate
hyperglycemia from 9 months of age, some researchers
disregard them as animal models of DR because retinal
changes of this model might be due to hereditary retinal
degeneration [76].
Models with definite retinal neovascularization
Unfortunately, most of above-mentioned animal models
do not demonstrate retinal neovascularization, a character-
istic finding in PDR patients. In this regard, researchers
often utilize animal models with definite retinal neovas-
cularization even though some of these models are not
characterized by hyperglycemia. Therefore, we should pay
more attention in the interpretation of data in these
models to find relevant findings regarding DR.
Kimba mice
Through microinjection of a DNA construct containing
the human VEGF165 gene, transgenic mice were gener-
ated [77]. Interestingly, pathologic features in this model
include extensive retinal neovascularization, increased
vascular leakage, and capillary non-perfusion, suggesting
the roles of VEGF in the development of these vascular
abnormalities [77,78].
OIR mice and rats
To induce retinal neovascularization in the OIR models,
newborn rodents are exposed to hyperoxia during early
developmental periods. The exact protocols are different
from species to species, but the principal mechanism of
animals is the same [47,49]. As for mice, newborn mice
are placed in a chamber with 75% oxygen from postnatal
day (P) 7 to P12. At P12, the central area of the retina
experiences regression of retinal vessels and further
ischemia [48]. Retinal neovascularization ensues at P14
and peaks at P17 [79]. With the intravenous injection of
fluorescein isothiocyanate-dextran or immunofluores-
cent staining with endothelial cell markers such as
isolectin-B4 or CD31, retinal neovascularization can be
visualized qualitatively and analyzed quantitatively with
the image processing program [48,79]. A representative
figure of the retina of OIR mice and the schematic
protocol of the induction of OIR in mice are demon-
strated in Figure 2 and 3, respectively.
Akimba mice
Models with definite retinal neovascularization usually
do not demonstrate hyperglycemia. Interestingly, cross-
ing the Akita mice with Kimba mice, the Akimba mice
(Ins2AkitaVEGF+/−) were generated to demonstrate hy-
perglycemia and retinal neovascularization at the same
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structural abnormalities such as thinning of PL and loss
of ganglion cells. In addition, vascular pathology is more
enhanced than parental strains, demonstrating severe ca-
pillary nonperfusion and retinal neovascularization. This
model might be appropriate to be utilized in the investi-
gation of the interaction between hyperglycemia and
growth factors such as VEGF in the pathogenesis of DR.
Diabetic Torii rats
This model is interesting in that it shows pathologic fea-
tures mimicking complications of PDR such as TRD and
VH. Glycosuria starts at approximately 20 weeks of age
and almost all male rats are evidenced to have diabetes
at 40 weeks of age [81]. Interestingly, histopathological
studies show TRD with fibrous proliferation and massive
hemorrhage in the anterior chamber in this model
[81,82]. Furthermore, this model also demonstrates
structural abnormalities such as acellular capillaries and
pericyte loss [82]. There is a significant reduction in
amplitudes and prolongation in implicit times of a-wave,
b-wave, and oscillatory potential with the aging and pro-
gression of diabetes in the electroretinographic analyses
[83]. However, there are definite differences between ret-
inal neovascularization in diabetic Torii rats and that in
human PDR in that this model develops retinal new ves-
sels without prominent retinal ischemia [84]. Possibly,
increase in angiogenic factors not from activation by
ischemic insults might be the cause of retinal neovas-
cularization in this model.
Dogs
Compared to zebrafish, mice, and rats, dogs are more
difficult to manipulate and maintain for the experiments.
Furthermore, as they are basically companion animals in
many cultural areas, there is much emotional resistance
to utilize dogs as laboratory animals. However, in the
development process of candidate therapeutics and the
investigation of pathologic events in DR, canine animal
models have several advantages as follows: 1) Dogs have
the macula which zebrafish, mice, and rats do not have.
In this regard, dogs have more similarity in the structure
of the retina with human. 2) The size of eyeball is almost
the same with human. Therefore, studies on phar-
macokinetic characteristics and various administration
methods are possible with canine animal models. 3) Fur-
thermore, machines for the evaluation of the retinal
structure and function such as optical coherence tomog-
raphy and electroretinography which are clinically uti-
lized can be easily applied to canine animal models.
Galactose-fed dogs
Galactose feeding results in pathologic changes corre-
sponding to human DR in beagles [85,86]. Interestingly,fluorescein angiography shows many characteristic find-
ings of human DR in the canine galactose-feeding model
such as IRMA, microaneurysm, intraretinal hemorrhage
and NVD. A weak point of this model for widespread
utilization might be long feeding periods for the induc-
tion of diabetes (more than 28 months) [85]. However,
this model can be attractive to researchers who want to
utilize canine animal models for the DR research.
OIR dogs
Similarly to OIR models in mice and rats, newborn bea-
gles are exposed to 95% to 100% oxygen continuously
for 4 days and returned to room air [50,87]. In this
model, retinal neovascularization with incomplete vascu-
larization of peripheral retina occurs to develop VH and
tractional retinal folds [50].
Monkeys
Type 2 diabetes occurs spontaneously in obese rhesus
monkeys [88,89]. As the ocular structure of rhesus mon-
keys are nearly same with that of human, microanigo-
pathic pathology in these monkeys looks similar to that
in DR patients. Pathologic findings in this model include
cotton-wool spots, intraretinal hemorrhages, hard exu-
dates, dot/blot hemorrhage, IRMA, and microaneu-
rysms. All of these features are exactly those in patients
with NPDR.
Conclusions
Purpose-based selection of appropriate animal models
Animal models have deepened our knowledge about the
pathogenesis of diseases and led the development of
valuable therapeutics to overcome pathologic conse-
quences of diseases. As for DR, we also owe advance-
ments in the investigation to validated animal models.
However, even validated animal models of DR have limi-
tations. Some do not demonstrate characteristics corre-
sponding to PDR, and others require too much time to
develop pathologic features of DR, making the process
of the evaluation of the therapeutic efficacy of candidate
drugs tedious. To investigate complex interactions
among different types of cells and multiple pathologic
mechanisms, it is not appropriate to utilized animal
models based on modification of a single factor. For
example, intravitreal injection of VEGF only might be
not an appropriate model for such a study. Likewise, re-
searchers should utilize animal models with retinal
neovascularization, not merely with induced hypergly-
cemia without new vessels, to evaluate the therapeutic
potential of candidate drugs on PDR. Furthermore,
researchers can select animal models with vascular per-
meability such as mice with induced hyperglycemia
(by streptozocin injection), db/db mice, Akita mice in
the process of drug development for ME.
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http://www.jbiomedsci.com/content/20/1/38Animal models of DR are based on hyperglycemia,
hypoxia, or introduction of VEGF gene. In this regard,
these animal models can be utilized to investigate patho-
genesis and potential therapeutics regarding these patho-
logic conditions. We expect that proper selection of
animal models according to the purpose of studies might
improve the potency of DR research to help to minimize
the risk of visual deterioration in DR patients from
vision-threatening complications.
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